SYM FINANCIAL Corp Takes Position in Medpace Holdings, Inc. (NASDAQ:MEDP)

SYM FINANCIAL Corp bought a new position in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) during the fourth quarter, according to its most recent disclosure with the SEC. The firm bought 964 shares of the company's stock, valued at approximately $320,000.

A number of other institutional investors also recently bought and sold shares of MEDP. Northwestern Mutual Wealth Management Co. increased its stake in shares of Medpace by 95.7% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 225 shares of the company's stock worth $93,000 after purchasing an additional 110 shares in the last quarter. Truist Financial Corp increased its stake in Medpace by 21.2% in the 2nd quarter. Truist Financial Corp now owns 3,700 shares of the company's stock worth $1,524,000 after buying an additional 648 shares in the last quarter. Cetera Investment Advisers raised its holdings in Medpace by 2.3% during the second quarter. Cetera Investment Advisers now owns 11,757 shares of the company's stock valued at $4,842,000 after acquiring an additional 263 shares during the period. Sanctuary Advisors LLC purchased a new position in shares of Medpace in the second quarter valued at about $1,346,000. Finally, HBW Advisory Services LLC bought a new position in shares of Medpace in the third quarter worth about $239,000. 77.98% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

MEDP has been the topic of several recent analyst reports. Robert W. Baird lifted their target price on Medpace from $354.00 to $362.00 and gave the company a "neutral" rating in a research note on Monday, January 27th. William Blair reissued an "outperform" rating on shares of Medpace in a report on Tuesday, October 22nd. TD Cowen cut their target price on shares of Medpace from $413.00 to $372.00 and set a "buy" rating for the company in a research note on Wednesday, October 23rd. Truist Financial decreased their price target on shares of Medpace from $415.00 to $397.00 and set a "hold" rating on the stock in a research note on Monday, October 14th. Finally, Baird R W lowered Medpace from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, October 23rd. Seven research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Hold" and an average target price of $381.44.

Medpace Price Performance

Shares of Medpace stock traded up $5.82 on Thursday, reaching $360.97. The company had a trading volume of 262,273 shares, compared to its average volume of 217,324. The firm's 50-day moving average price is $343.17 and its two-hundred day moving average price is $350.31. Medpace Holdings, Inc. has a 1 year low of $301.81 and a 1 year high of $459.77. The firm has a market cap of $11.22 billion, a price-to-earnings ratio of 31.61, a P/E/G ratio of 1.79 and a beta of 1.36.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.